The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India

Background: PDL-1 inhibitors have emerged as the new standard of care for second line treatment of NSCLC. Methods: Eligible patients included, histologically proven NSCLC, ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1 or 2, age 18 years and above, availability of pre-treatment...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Waseem Abbas, Rudra Prasad Acharya, Archit Pandit, Saurabh Gupta, Ranga Raju Rao
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2020-01-01
Edice:	South Asian Journal of Cancer
Témata:	immunotherapy in lung cancer nivolumab in carcinoma lung real-world data of nivolumab
On-line přístup:	http://www.thieme-connect.de/DOI/DOI?10.4103/sajc.sajc_111_19
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!